Clinical trial / 2013
Potassium citrate supplementation for 24 months improved bone density, microarchitecture, and FRAX scores in healthy older adults.
In a randomized, double-blind, placebo-controlled trial, 201 healthy older adults without osteoporosis were assigned to 60 mEq of oral potassium citrate daily or placebo for 24 months alongside calcium and vitamin D. Potassium citrate increased lumbar spine areal BMD from baseline by 1.7 ± 1.5% net of placebo (95% CI 1.0-2.3, P < 0.001). Trabecular densities also increased at the nondominant tibia (1.3 ± 1.3%, P < 0.001) and nondominant radius (2.0 ± 2.0%, P < 0.001), alongside improvements in trabecular bone volume/tissue volume (0.9 ± 0.8%), thickness (1.5 ± 1.6%), and number (1.9 ± 1.8%, all P < 0.05). Potassium citrate also significantly decreased FRAX fracture prediction scores in both sexes.
- Study type
- Randomized, double-blind, placebo-controlled trial
- Who was studied
- 201 healthy men and women over 65 years old without osteoporosis
- What was measured
- Lumbar spine areal BMD, volumetric density, microarchitecture, FRAX score
THE PAPER
Effect of potassium citrate on bone density, microarchitecture, and fracture risk in healthy older adults without osteoporosis: a randomized controlled trial.
Jehle S, Hulter HN, Krapf R. J Clin Endocrinol Metab, 2013.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.